Fig. 6: Atezolizumab counteracts defective SPOP-LMNB2-PD-L1 axis-induced immune escape of HCC in vivo.
From: LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma
A Mode diagram of Atezolizumab injection in C57BL/6 J mice with a subcutaneous tumor. B Schematic representation of xenograft tumors of sh-NC + EV, sh-SPOP + EV, sh-SPOP + sh-LMNB2 + EV, SPOP + LMNB2 + sh-NC, SPOP + LMNB2-△SBC + sh-NC, and SPOP-M35L + LMNB2 + sh-NC groups in DMSO or Atezolizumab. C Weight of xenograft tumors in the above groups. D Volume of xenograft tumor in the above group. E IHC staining of SPOP, LMNB2, PD-L1, CD3, and CD8 in xenograft tumors. Scale bar, 200 μm. F Statistical analysis of the IHC staining scores of SPOP, LMNB2, PD-L1, CD3, and CD8 in xenograft tumors. Data are shown as mean ± SD (n ≥ 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns p ≥ 0.05.
